000143371 001__ 143371
000143371 005__ 20240229112550.0
000143371 0247_ $$2doi$$a10.3390/cancers11030379
000143371 0247_ $$2pmid$$apmid:30884910
000143371 037__ $$aDKFZ-2019-00959
000143371 041__ $$aeng
000143371 082__ $$a610
000143371 1001_ $$00000-0001-8363-2668$$aAkbaba, Sati$$b0
000143371 245__ $$aBimodal Radiotherapy with Active Raster-Scanning Carbon Ion Radiotherapy and Intensity-Modulated Radiotherapy in High-Risk Nasopharyngeal Carcinoma Results in Excellent Local Control.
000143371 260__ $$aBasel$$bMDPI$$c2019
000143371 3367_ $$2DRIVER$$aarticle
000143371 3367_ $$2DataCite$$aOutput Types/Journal article
000143371 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1554964390_13236
000143371 3367_ $$2BibTeX$$aARTICLE
000143371 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143371 3367_ $$00$$2EndNote$$aJournal Article
000143371 520__ $$aBackground: In this analysis, we aimed to present the first results of carbon ion radiotherapy (CIRT), which is known for its conformal dose distribution and increased biological effectiveness in the treatment of high-risk nasopharyngeal carcinoma (NPC). Methods: We retrospectively analyzed twenty-six consecutive patients who had been treated at our center with CIRT for high-risk NPC between 2009 and 2018. Carbon ion (C12) boost was applied in a bimodal setting combined with intensity-modulated radiotherapy (IMRT) base plan. The median cumulative total dose was 74 Gy (RBE), and patients with inoperable (n = 17, 65%) or incompletely resected (n = 7, 27%) tumors were included in the analysis. Overall, 81% received concomitant chemotherapy (n = 21). Results: The median follow-up time was 40 months (range 10⁻97 months) for all patients. At the last follow-up, 92% of the patients were still alive. We could identify excellent tumor response with complete tumor remission (CR) in 60% (n = 15/25), partial tumor remission (PR) in 20% (n = 5/25), and stable disease (SD) in 12% (n = 3/25) of the patients according to the RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Despite unfavorable tumor characteristics, only one patient showed a locally in-field recurrence after 56 months (4%) and another patient a locoregional recurrence in the unilateral cervical lymph nodes after 21 months (4%). The 2-year local control (LC), distant progression-free survival (DPFS), and overall survival (OS) were 95%, 93%, and 100% and the estimated 5-year LC, DPFS, and OS were 90%, 86%, and 86%, respectively. Overall, treatment was tolerated well with 20% acute and 16% chronic grade 3 side effects. No toxicity greater than grade 3 occurred. Conclusion: Bimodal radiotherapy including IMRT and active raster-scanning CIRT for high-risk nasopharyngeal cancer is a safe treatment method resulting in moderate toxicity and excellent local control. A larger patient number and longer follow-up time would be necessary to strengthen the current findings.
000143371 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000143371 588__ $$aDataset connected to CrossRef, PubMed,
000143371 7001_ $$aHeld, Thomas$$b1
000143371 7001_ $$aLang, Kristin$$b2
000143371 7001_ $$aForster, Tobias$$b3
000143371 7001_ $$00000-0002-2537-0185$$aFederspil, Philippe$$b4
000143371 7001_ $$0P:(DE-HGF)0$$aHerfarth, Klaus$$b5
000143371 7001_ $$aHäfner, Matthias$$b6
000143371 7001_ $$aPlinkert, Peter$$b7
000143371 7001_ $$0P:(DE-HGF)0$$aRieken, Stefan$$b8
000143371 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b9$$udkfz
000143371 7001_ $$00000-0001-8463-514X$$aAdeberg, Sebastian$$b10
000143371 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers11030379$$gVol. 11, no. 3, p. 379 -$$n3$$p379 -$$tCancers$$v11$$x2072-6694$$y2019
000143371 909CO $$ooai:inrepo02.dkfz.de:143371$$pVDB
000143371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000143371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000143371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000143371 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000143371 9141_ $$y2019
000143371 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2017
000143371 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143371 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143371 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143371 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143371 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000143371 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000143371 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000143371 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000143371 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143371 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143371 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143371 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143371 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143371 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143371 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2017
000143371 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x0
000143371 980__ $$ajournal
000143371 980__ $$aVDB
000143371 980__ $$aI:(DE-He78)E050-20160331
000143371 980__ $$aUNRESTRICTED